Non-cardiovascular effects associated with statins

作者: Chintan S Desai , Seth S Martin , Roger S Blumenthal , None

DOI: 10.1136/BMJ.G3743

关键词:

摘要: Statins form the pharmacologic cornerstone of primary and secondary prevention atherosclerotic cardiovascular disease. In addition to beneficial effects, statins seem have multiple non-cardiovascular effects. Although early concerns about statin induced hepatotoxicity cancer subsided owing reassuring evidence, two most common that clinicians are myopathy diabetes. Randomized controlled trials suggest associated with a modest increase in risk myositis but not myalgia. Severe (rhabdomyolysis) is rare often linked regimen no longer recommended (simvastatin 80 mg). meta-analyses an diabetes statins, particularly higher intensity regimens people or more components metabolic syndrome. Other effects covered this review contrast nephropathy, cognition, cataracts, erectile dysfunction, venous thromboembolism. Currently, systematic reviews clinical practice guidelines indicate benefits generally outweigh harms patients above certain threshold risk. Literature also accumulating on potential which could lead novel applications class drug future.

参考文章(94)
J Wardle, J Armitage, R Collins, K Wallendszus, A Keech, A Lawson, Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ. ,vol. 313, pp. 75- 78 ,(1996) , 10.1136/BMJ.313.7049.75
Michael J. Blaha, Seth S. Martin, How Do Statins Work? Journal of the American College of Cardiology. ,vol. 62, pp. 2392- 2394 ,(2013) , 10.1016/J.JACC.2013.08.1626
Judith Hsia, Jean G. MacFadyen, John Monyak, Paul M. Ridker, Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin Journal of the American College of Cardiology. ,vol. 57, pp. 1666- 1675 ,(2011) , 10.1016/J.JACC.2010.09.082
Alawi A. Alsheikh-Ali, Prasad V. Maddukuri, Hui Han, Richard H. Karas, Effect of the Magnitude of Lipid Lowering on Risk of Elevated Liver Enzymes, Rhabdomyolysis, and Cancer: Insights From Large Randomized Statin Trials Journal of the American College of Cardiology. ,vol. 50, pp. 409- 418 ,(2007) , 10.1016/J.JACC.2007.02.073
Robert J Glynn, Eleanor Danielson, Francisco AH Fonseca, Jacques Genest, Antonio M Gotto Jr, John JP Kastelein, Wolfgang Koenig, Peter Libby, Alberto J Lorenzatti, Jean G MacFadyen, Børge G Nordestgaard, James Shepherd, James T Willerson, Paul M Ridker, None, A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism The New England Journal of Medicine. ,vol. 360, pp. 1851- 1861 ,(2009) , 10.1056/NEJMOA0900241
SLCO1B1 variants and statin-induced myopathy--a genomewide study The New England Journal of Medicine. ,vol. 359, pp. 789- 799 ,(2008) , 10.1056/NEJMOA0801936